Actions of vasoactive intestinal peptide on the rat adrenal zona glomerulosa.
Previous studies, by this group and others, have shown that vasoactive intestinal peptide (VIP) stimulates aldosterone secretion, and that the actions of VIP on aldosterone secretion by the rat adrenal cortex are blocked by beta adrenergic antagonists, suggesting that VIP may act by the local release of catecholamines. The present studies were designed to test this hypothesis further, by measuring catecholamine release by adrenal capsular tissue in response to VIP stimulation. Using intact capsular tissue it was found that VIP caused a dose-dependent increase in aldosterone secretion, with a concomitant increase in both adrenaline and noradrenaline release. The effects of VIP on aldosterone secretion were inhibited by atenolol, a beta1 adrenergic antagonist, but not by ICI-118,551, a beta2 adrenergic antagonist. Binding studies were carried out to investigate VIP receptors. It was found that adrenal zona glomerulosa tissue from control rats contained specific VIP binding sites (Bmax 853+/-101 fmol/mg protein; Kd 2.26+/-0.45 nmol/l). VIP binding was not displaced by ACTH, angiotensin II or by either of the beta adrenergic antagonists. The response to VIP in adrenals obtained from rats fed a low sodium diet was also investigated. Previous studies have found that adrenals from animals on a low sodium diet exhibit increased responsiveness to VIP. Specific VIP binding sites were identified, although the concentration or affinity of binding sites in the low sodium group was not significantly different from the controls. In the low sodium group VIP was found to increase catecholamine release to the same extent as in the control group, however, in contrast to the control group, the adrenal response to VIP was not altered by adrenergic antagonists in the low sodium group. These data provide strong support for the hypothesis that VIP acts by the local release of catecholamines in adrenal zona glomerulosa tissue in normal animals. It does not appear that VIP acts through the same mechanism in animals maintained on a low sodium diet. The mechanism by which VIP stimulates aldosterone in this group remains to be determined.
Hinson
J P
JP
Molecular and Cellular Biology Section, Division of Biomedical Sciences, St Bartholomew's and The Royal London School of Medicine and Dentistry, Queen Mary and Westfield College, Mile End Road, London E1 4NS, UK.
Puddefoot
J R
JR
Kapas
S
S
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000450:Aldosterone / Q000097:blood / Q000378:metabolism*; D000704:Analysis of Variance; D000818:Animals; D001262:Atenolol / Q000494:pharmacology; D002395:Catecholamines / Q000097:blood / Q000378:metabolism*; D046508:Culture Techniques; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000097:blood / Q000378:metabolism; D005260:Female; D008297:Male; D009638:Norepinephrine / Q000097:blood / Q000378:metabolism; D011412:Propanolamines / Q000494:pharmacology; D011485:Protein Binding; D051381:Rats; D017208:Rats, Wistar; D018005:Receptors, Vasoactive Intestinal Peptide / Q000032:analysis; D012982:Sodium, Dietary / Q000008:administration & dosage; D013268:Stimulation, Chemical; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*; D015384:Zona Glomerulosa / Q000187:drug effects / Q000378:metabolism*
D000319:Adrenergic beta-Antagonists; D002395:Catecholamines; D011412:Propanolamines; D018005:Receptors, Vasoactive Intestinal Peptide; D012982:Sodium, Dietary; D014660:Vasoactive Intestinal Peptide; C026777:ICI 118551; D000450:Aldosterone; D001262:Atenolol; D009638:Norepinephrine; D004837:Epinephrine